Insys Therapeutics
Chandler
About Insys Therapeutics
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $1K – $10K
- Total funding: $2.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2011)
- Ticker: otcpink:INSYQ
- Website: insysrx.com
- Phone: 6029102627
Industries & Categories
Biotechnology, Manufacturing, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/insys-therapeutics-774825 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.